By 
Biotechnology firm Novavax Inc. has scored the recommendation of a unit of the Food and Drug Administration (FDA) for its COVID-19 vaccine for 18 years and older.
Source: Novavax
NVAX is down 0.79%, while MRND is up 1.28%.
President and Chief Executive Officer Stanley Erck said the latest recommendation indicates that the FDA Vaccines and Related Biological Products Advisory Committee noted the strength of the vaccine.
The recommendation scored 21 votes in support and got no votes against. It had one abstention, which sought to recommend that the FDA also push for the Emergency Use Authorization (EUA) for the same age group.
The committee took into consideration data from Novavax’s Phase 3 clinical trial, which covered 30,000 participants aged 18 years and older in the United States and Mexico.
The clinical trial indicated that the vaccine had a 90.4% efficacy among the trial respondents, with “low” serious and severe adverse events jabbed with the vaccine and placebo groups.
Comments